Roivant's Lung Drug Just Posted Data That Has Wall Street Buzzing

And here's the kicker on safety: cough, which you'd worry about with an inhaled lung drug, actually occurred less often with mosliciguat (12.1%) than with placebo (18.2%). The drug was broadly well tolerated.

How Mosliciguat Works (the Simple Version)

Your body uses a molecule called nitric oxide to relax blood vessels. In PH-ILD patients, that signaling pathway is broken. Mosliciguat is what scientists call a soluble guanylate cyclase (sGC) activator, which is a fancy way of saying it kickstarts the same relaxation pathway that nitric oxide would normally trigger.

The clever part is the delivery method. Because it's inhaled, the drug goes straight to the lungs rather than flooding the entire body. That targeted approach is like using a sniper rifle instead of a shotgun: you get the effect where you need it, with fewer side effects elsewhere. It's also a once-daily inhaler, which is a much easier ask than some of the alternatives on the market.

The Blockbuster Question

Let's talk about sales projections. Leerink Partners analyst David Risinger suggested a $10 billion-plus bull case for Roivant's aggregate pipeline potential. But context matters enormously here.

That figure assumes Roivant doesn't stop at PH-ILD. It assumes the drug gets developed and approved in additional forms of pulmonary hypertension, expanding the patient pool dramatically. The entire PAH (pulmonary arterial hypertension) market is already worth roughly $8.5 to $10.5 billion in 2026, so Roivant would essentially need to capture a huge share of an expanded market.

Other analysts are more measured. Guggenheim estimated about $3 billion in peak sales for PH-ILD alone. J.P. Morgan had previously pegged risk-adjusted peak sales at $1.5 billion before the data dropped, implying the strong results could push that estimate meaningfully higher.

So the realistic range looks more like $1.5 to $3 billion for the current indication, with broader pipeline expansion representing the dream scenario. Still, even the conservative end of that range would make mosliciguat a blockbuster several times over.

The Competition Won't Just Watch

Roivant isn't operating in a vacuum. The pulmonary hypertension space is fiercely competitive, with heavyweights like Merck, United Therapeutics, Bayer, Gilead, and Pfizer all jockeying for position.

Merck's sotatercept has been a major story in pulmonary arterial hypertension, working through a completely different mechanism (activin signaling rather than the nitric oxide pathway). United Therapeutics dominates the prostacyclin corner of the market with its treprostinil franchise. There are also newer entrants like seralutinib, an inhaled kinase inhibitor in PAH trials.

But mosliciguat's combination of strong efficacy data, clean safety profile, and convenient once-daily inhaled delivery could carve out a meaningful niche, especially in PH-ILD where options remain scarce.

What Comes Next

Roivant has already launched a Phase 3 trial called PHrontier, with enrollment underway. That's unusually fast, suggesting the company had enough confidence (and regulatory alignment) to start the pivotal study before the Phase 2 readout even hit.

If the Phase 3 data holds up, Roivant could be looking at a regulatory filing within a few years. The company built its reputation on the "Vant model," creating focused subsidiaries (in this case, Pulmovant) designed to move drugs through development quickly. That structure, originally the brainchild of founder Vivek Ramaswamy, is being put to its biggest test yet.

The Bottom Line

Phase 2 data is promising, not proof. Plenty of drugs have posted gorgeous mid-stage numbers only to stumble in Phase 3. But the combination of a large unmet need, a differentiated mechanism, strong efficacy across multiple endpoints, and a clean safety profile makes mosliciguat one of the most compelling pipeline stories in respiratory medicine right now.

Wall Street's most bullish projections may be aspirational. But even the skeptics are modeling blockbuster potential. For a drug that most investors weren't paying attention to six months ago, that's one heck of a coming-out party.

The Immunotherapy Target Everyone Gave Up On Just Came Back to Life

Every major pharma company tried to make OX40 agonists work in cancer, and every single one failed. Now Inhibrx's hexavalent approach just delivered Phase 2 results that could resurrect an entire abandoned drug class.